MET signaling regulates glioblastoma stem cells.

Glioblastomas multiforme (GBM) contain highly tumorigenic, self-renewing populations of stem/initiating cells [glioblastoma stem cells (GSC)] that contribute to tumor propagation and treatment resistance. However, our knowledge of the specific signaling pathways that regulate GSCs is limited. The MET tyrosine kinase is known to stimulate the survival, proliferation, and invasion of various cancers including GBM. Here, we identified a distinct fraction of cells expressing a high level of MET in human primary GBM specimens that were preferentially localized in perivascular regions of human GBM biopsy tissues and were found to be highly clonogenic, tumorigenic, and resistant to radiation. Inhibition of MET signaling in GSCs disrupted tumor growth and invasiveness both in vitro and in vivo, suggesting that MET activation is required for GSCs. Together, our findings indicate that MET activation in GBM is a functional requisite for the cancer stem cell phenotype and a promising therapeutic target.

[1]  W. Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[2]  L. Parada,et al.  Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells , 2012, Cell.

[3]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[4]  P. Ma,et al.  MET signaling: novel targeted inhibition and its clinical development in lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Peter Dirks,et al.  Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.

[6]  F. Marincola,et al.  Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[7]  J. Rich,et al.  Twisted tango: brain tumor neurovascular interactions , 2011, Nature Neuroscience.

[8]  L. Appleman.  MET signaling pathway: a rational target for cancer therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Martin Glas,et al.  c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype , 2011, Proceedings of the National Academy of Sciences.

[10]  E. Medico,et al.  Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. , 2011, Journal of the National Cancer Institute.

[11]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[12]  J. Baselga,et al.  TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.

[13]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[14]  R. McLendon,et al.  Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.

[15]  T. Yap,et al.  Targeting the HGF/c-Met Axis: State of Play , 2010, Molecular Cancer Therapeutics.

[16]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[17]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[18]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[19]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[20]  M. Roger,et al.  Endogenous Hepatocyte Growth Factor Is a Niche Signal for Subventricular Zone Neural Stem Cell Amplification and Self‐Renewal , 2009, Stem cells.

[21]  D. Schiff,et al.  Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy , 2009, Molecular Cancer Therapeutics.

[22]  D. Nam,et al.  Prospective identification of cancer stem cells with the surface antigen CD133. , 2009, Methods in molecular biology.

[23]  Do-Hyun Nam,et al.  Prognostic significance of c‐Met expression in glioblastomas , 2009, Cancer.

[24]  T. Park,et al.  LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. , 2008, Bioconjugate chemistry.

[25]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[26]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[27]  S. Bidlingmaier,et al.  The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells , 2008, Journal of Molecular Medicine.

[28]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[29]  Peter Canoll,et al.  Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. , 2008, Neurosurgery.

[30]  P. Comoglio,et al.  Silencing the MET oncogene leads to regression of experimental tumors and metastases , 2008, Oncogene.

[31]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[32]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer Cell.

[33]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[34]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[35]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[36]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[37]  P. Comoglio,et al.  Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.

[38]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[39]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[40]  J. Laterra,et al.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. , 2005, Neuro-oncology.

[41]  Mitchel S Berger,et al.  Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.

[42]  J. Laterra,et al.  Targeting the c-Met Pathway Potentiates Glioblastoma Responses to γ-Radiation , 2005, Clinical Cancer Research.

[43]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[44]  J. Laterra,et al.  Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[46]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[47]  J. Christensen,et al.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.

[48]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[49]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[50]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[51]  K. Nabeshima,et al.  Expression of c‐Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study , 1997, Histopathology.